MDT-AP-0386
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 42
- os_event
- false
- age_years
- 4
- sex
- M
- new_clusters
- C4
- umap1_2d
- 2.726796385
- umap2_2d
- 5.077305118
- umap1_3d
- 0.410061486
- umap2_3d
- -0.421650323
- umap3_3d
- -0.670386124
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.390
- PANCREAS_BETA_CELLS+0.360
- ANGIOGENESIS+0.350
- G2M_CHECKPOINT+0.330
- ALLOGRAFT_REJECTION+0.310
- MYC_TARGETS_V1+0.310
- SPERMATOGENESIS+0.300
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.260
- KRAS_SIGNALING_UP+0.260
- ESTROGEN_RESPONSE_LATE+0.240
Top 10 suppressed
- WNT_BETA_CATENIN_SIGNALING-0.330
- HEME_METABOLISM-0.310
- PI3K_AKT_MTOR_SIGNALING-0.310
- APICAL_JUNCTION-0.290
- MYC_TARGETS_V2-0.270
- NOTCH_SIGNALING-0.260
- P53_PATHWAY-0.250
- UV_RESPONSE_UP-0.230
- PROTEIN_SECRETION-0.220
- MITOTIC_SPINDLE-0.210
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-0049 | Med | Medulloblastoma | 0.785 |
| 2 | MNG1120 | — | — | 0.703 |
| 3 | MDT-AP-2385 | Med | Medulloblastoma | 0.680 |
| 4 | MDT-AP-0016 | Med | Medulloblastoma | 0.671 |
| 5 | MDT-AP-0005 | Med | Medulloblastoma | 0.654 |
| 6 | SRR13311166 | — | — | 0.643 |
| 7 | MNG24 | — | — | 0.631 |
| 8 | MDT-AP-0565 | Med | Medulloblastoma | 0.629 |
| 9 | MDT-AP-0809 | Med | Medulloblastoma | 0.622 |
| 10 | SRR13311167 | — | — | 0.609 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 23 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.390 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.360 | Cobimetinib | — uncovered |
| ANGIOGENESIS | 0.350 | Remibrutinib | — uncovered |
| G2M_CHECKPOINT | 0.330 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.310 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.310 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.300 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.260 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.260 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.240 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.220 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.210 | Inavolisib | — uncovered |
| COMPLEMENT | 0.180 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.150 | Inavolisib | — uncovered |
| COAGULATION | 0.140 | Binimetinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.140 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.070 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.070 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.050 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.030 | Remibrutinib | — uncovered |